TCGA-EW-A1IZ-01A-11R-A13Q-07
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
- overall_survival_months
- 18
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.550
- INTERFERON_GAMMA_RESPONSE+0.380
- IL6_JAK_STAT3_SIGNALING+0.320
- OXIDATIVE_PHOSPHORYLATION+0.300
- INTERFERON_ALPHA_RESPONSE+0.240
- DNA_REPAIR+0.230
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.230
- COMPLEMENT+0.190
- IL2_STAT5_SIGNALING+0.170
- P53_PATHWAY+0.160
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.440
- HEDGEHOG_SIGNALING-0.390
- UV_RESPONSE_DN-0.380
- PROTEIN_SECRETION-0.360
- NOTCH_SIGNALING-0.330
- CHOLESTEROL_HOMEOSTASIS-0.250
- MITOTIC_SPINDLE-0.250
- GLYCOLYSIS-0.240
- TGF_BETA_SIGNALING-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR9879287 | — | cohortA1 | 0.856 |
| 2 | TCGA-LL-A5YO-01A-21R-A28M-07 | — | D | 0.855 |
| 3 | TCGA-TN-A7HL-01A-11R-A34R-07 | — | — | 0.841 |
| 4 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.829 |
| 5 | TCGA-E2-A1B6-01A-31R-A12P-07 | — | D | 0.816 |
| 6 | TCGA-64-5778-01A-01R-1628-07 | — | cohortA1 | 0.805 |
| 7 | SRR25617828 | — | D | 0.804 |
| 8 | 8cb3ba59-cfa2-4529-87a4-80d3f7be1332 | — | — | 0.803 |
| 9 | TCGA-LL-A5YN-01A-11R-A28M-07 | — | B | 0.801 |
| 10 | TCGA-CV-A45T-01A-11R-A24H-07 | — | — | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.170 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.160 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.150 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.130 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.110 | Idelalisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.080 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |